Form 4: SeaStar Medical Director John Neuman Increases Stake in Company
SEC Form 4 Filing
Director John Neuman has been steadily increasing his holdings in SeaStar Medical through a series of open market purchases.
Summary
- John Neuman, a director of SeaStar Medical Holding Corp, has been actively purchasing the company's common stock.
- Between June 14, 2024, and December 11, 2024, Neuman acquired a total of 40,000 shares through multiple transactions.
- The purchases were made at varying prices, with weighted average prices ranging from $2.0405 to $5.2396 per share.
- As of the latest reported transaction on December 11, 2024, Neuman directly owns 40,000 shares of SeaStar Medical.
- The reporting of these transactions was delayed due to an administrative error.
Sentiment
Score: 6
Explanation: The sentiment is neutral to slightly positive. The director's purchases suggest confidence, but the late filing is a minor concern.
Positives
- A director's increased investment in the company may signal confidence in its future prospects.
Negatives
- The late reporting of these transactions due to an administrative error could raise concerns about internal controls.
Risks
- The Form 4 filing itself doesn't inherently indicate risks, but the late filing suggests potential weaknesses in compliance procedures.
- The price paid per share varies widely, which could indicate volatility in the stock price.
Industry Context
Form 4 filings are a routine part of regulatory compliance for publicly traded companies, providing transparency into insider transactions. Monitoring these filings can offer insights into management's sentiment and potential future performance.
Comparison to Industry Standards
- Form 4 filings are standard practice for publicly traded companies, and the information disclosed is consistent with regulatory requirements.
- Comparable companies would also have similar filings when insiders trade their company's stock.
Stakeholder Impact
- Shareholders may view the director's stock purchases as a positive signal.
- The late filing could raise concerns among stakeholders about the company's internal controls.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | John Neuman purchased 10,000 shares at a weighted average price of $3.6905. |
| 06/17/2024 | John Neuman purchased 10,000 shares at a weighted average price of $4.3521. |
| 08/15/2024 | John Neuman purchased 10,000 shares at a weighted average price of $5.2396. |
| 12/11/2024 | John Neuman purchased 10,000 shares at a weighted average price of $2.0405. |
| 02/27/2025 | Date of signature for the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.